ZNRF2

Summary

ZNRF2 (zinc and ring finger 2, HGNC:22316) is a protein-coding gene on chromosome 7p14.3, encoding E3 ubiquitin-protein ligase ZNRF2 (Q8NHG8). E3 ubiquitin-protein ligase that plays a role in the establishment and maintenance of neuronal transmission and plasticity.

Enables ubiquitin protein ligase activity. Involved in positive regulation of autophagosome-lysosome fusion. Located in cytoplasmic vesicle membrane; nuclear lumen; and plasma membrane. Part of protein-containing complex. Is active in intracellular membrane-bounded organelle.

Source: NCBI Gene 223082 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 12 total
• MANE Select transcript: NM_147128

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22316
Approved symbol	ZNRF2
Name	zinc and ring finger 2
Location	7p14.3
Locus type	gene with protein product
Status	Approved
Aliases	RNF202
Ensembl gene	ENSG00000180233
Ensembl biotype	protein_coding
OMIM	612061
Entrez	223082

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000323037, ENST00000459998, ENST00000937786, ENST00000953272, ENST00000953273

RefSeq mRNA: 1 — MANE Select: NM_147128 NM_147128

CCDS: CCDS5426

Canonical transcript exons

ENST00000323037 — 5 exons

Exon	Start	End
ENSE00001220250	30355728	30355833
ENSE00001264445	30323642	30323737
ENSE00001264455	30362377	30362456
ENSE00001375265	30284597	30285826
ENSE00001819686	30366035	30367689

Expression profiles

Bgee: expression breadth ubiquitous, 216 present calls, max score 89.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.5695 / max 154.1745, expressed in 1647 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
77978	3.5225	1271
77981	2.8435	1095
77980	1.2274	740
77979	0.5525	340
77977	0.5178	259
77983	0.4544	264
77982	0.4512	250

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.32	gold quality
buccal mucosa cell	CL:0002336	88.47	silver quality
monocyte	CL:0000576	87.58	gold quality
calcaneal tendon	UBERON:0003701	87.55	gold quality
leukocyte	CL:0000738	87.36	gold quality
rectum	UBERON:0001052	86.72	gold quality
islet of Langerhans	UBERON:0000006	85.91	gold quality
mucosa of transverse colon	UBERON:0004991	84.72	gold quality
secondary oocyte	CL:0000655	84.12	gold quality
right lobe of liver	UBERON:0001114	83.96	gold quality
jejunal mucosa	UBERON:0000399	82.92	gold quality
cortical plate	UBERON:0005343	82.71	gold quality
colonic mucosa	UBERON:0000317	82.58	gold quality
smooth muscle tissue	UBERON:0001135	82.26	gold quality
vermiform appendix	UBERON:0001154	81.99	gold quality
mucosa of sigmoid colon	UBERON:0004993	81.32	gold quality
epithelial cell of pancreas	CL:0000083	81.29	silver quality
testis	UBERON:0000473	81.06	gold quality
duodenum	UBERON:0002114	80.97	gold quality
right testis	UBERON:0004534	80.87	gold quality
adult mammalian kidney	UBERON:0000082	80.69	gold quality
left testis	UBERON:0004533	80.56	gold quality
liver	UBERON:0002107	80.42	gold quality
granulocyte	CL:0000094	80.39	gold quality
pancreas	UBERON:0001264	80.28	gold quality
sperm	CL:0000019	80.22	gold quality
gall bladder	UBERON:0002110	80.18	gold quality
lymph node	UBERON:0000029	80.00	gold quality
tendon	UBERON:0000043	79.82	gold quality
oral cavity	UBERON:0000167	79.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.93

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP63

miRNA regulators (miRDB)

188 targeting ZNRF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345

Literature-anchored findings (GeneRIF, showing 6)

• identification of ZNRF2; data suggest that ZNRF proteins play a role in the establishment and maintenance of neuronal transmission and plasticity via their ubiquitin ligase activity [ZNRF2] (PMID:14561866)
• ZNRF1 and ZNRF2 are new players in regulation of the ubiquitous Na(+)/K(+)ATPase that is tuned to changing demands in many physiological contexts. (PMID:22797923)
• These findings uncover ZNRF2 as a component of the amino acid sensing machinery that acts upstream of Rag-GTPases and the V-ATPase to activate mTORC1. (PMID:27244671)
• Results detected significantly higher levels of ZNRF2 in osteosarcoma cells (OS) and provide evidence that ZNRF2 enhances OS cell growth and improves survival against doxorubicin. (PMID:28416774)
• The findings obtained in the present study indicate that TTN-AS1 facilitated PTC progression by regulating the miR-153-3p/ZNRF2 axis and activating the PI3K/Akt/mTOR pathway. (PMID:30811764)
• A pancancer analysis of the oncogenic role of ZNRF2 in human tumours. (PMID:37551845)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	znrf2b	ENSDARG00000098792
mus_musculus	Znrf2	ENSMUSG00000058446
rattus_norvegicus	Znrf2	ENSRNOG00000049057
drosophila_melanogaster	CG14435	FBGN0029911
caenorhabditis_elegans	Y71F9AL.10	WBGENE00022115

Paralogs (2): RNF11 (ENSG00000123091), ZNRF1 (ENSG00000186187)

Protein

Protein identifiers

E3 ubiquitin-protein ligase ZNRF2 — Q8NHG8 (reviewed: Q8NHG8)

Alternative names: Protein Ells2, RING finger protein 202, RING-type E3 ubiquitin transferase ZNRF2, Zinc/RING finger protein 2

All UniProt accessions (2): Q8NHG8, A0A090N8Y8

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase that plays a role in the establishment and maintenance of neuronal transmission and plasticity. Ubiquitinates the Na(+)/K(+) ATPase alpha-1 subunit/ATP1A1 and thereby influences its endocytosis and/or degradation. Acts also as a positive regulator of mTORC1 activation by amino acids, which functions upstream of the V-ATPase and of Rag-GTPases. In turn, phosphorylation by mTOR leads to its inhibition via targeting to the cytosol allowing a self-regulating feedback mechanism.

Subunit / interactions. Interacts with UBE2N. Interacts with ZNRF1. Interacts (when phosphorylated) with YWHAE.

Subcellular location. Endosome membrane. Lysosome membrane. Presynaptic cell membrane. Cytoplasm.

Tissue specificity. Highly expressed in the brain, with higher expression during development than in adult. Expressed also in mammary glands, testis, colon and kidney.

Post-translational modifications. Phosphorylated; leading to binding to YWHAE. Phosphorylated by MTOR at Ser-145 and dephosphorylated by PP6C. Ser-145 phosphorylation stimulates vesicle-to-cytosol translocation.

Domain organisation. The RING-type zinc finger domain is required for E3 ligase activity.

Pathway. Protein modification; protein ubiquitination.

RefSeq proteins (1): NP_667339* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR051878	ZNRF_ubiq-protein_ligase	Family

Pfam: PF13639

UniProt features (24 total): modified residue 11, mutagenesis site 4, compositionally biased region 4, initiator methionine 1, chain 1, lipid moiety-binding region 1, zinc finger region 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NHG8-F1	67.87	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (12): 25, 82, 89, 113, 116, 135, 145, 151, 193, 2, 19, 21

Mutagenesis-validated functional residues (4):

Position	Phenotype
2	complete loss of binding to atp1a1.
19	counteracts the n-myristoyl-mediated targeting of znrf2 to membranes.
82	partial decrease of ywhae binding upon igf1 stimulation.
145	partial decrease of ywhae binding upon igf1 stimulation. more distinct membranal localization.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation

MSigDB gene sets: 217 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, GOBP_REGULATION_OF_VESICLE_FUSION, CCAWYNNGAAR_UNKNOWN, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, GOCC_VACUOLAR_MEMBRANE, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOBP_VESICLE_ORGANIZATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_MEMBRANE_FUSION, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, CTATGCA_MIR153

GO Biological Process (5): proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), protein K48-linked ubiquitination (GO:0070936), positive regulation of autophagosome-lysosome fusion (GO:0160177), protein ubiquitination (GO:0016567), intracellular potassium ion homeostasis (GO:0030007)

GO Molecular Function (4): zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (15): fibrillar center (GO:0001650), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), lysosomal membrane (GO:0005765), cytosol (GO:0005829), plasma membrane (GO:0005886), endosome membrane (GO:0010008), membrane (GO:0016020), cytoplasmic vesicle membrane (GO:0030659), protein-containing complex (GO:0032991), presynaptic membrane (GO:0042734), lysosome (GO:0005764), endosome (GO:0005768), cell projection (GO:0042995), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
cytoplasmic vesicle	2
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
protein polyubiquitination	1
positive regulation of vesicle fusion	1
autophagosome-lysosome fusion	1
protein modification by small protein conjugation	1
intracellular monoatomic cation homeostasis	1
potassium ion homeostasis	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
catalytic activity	1
cation binding	1
nucleolus	1
nuclear lumen	1
intracellular anatomical structure	1
lysosome	1
lytic vacuole membrane	1
cytoplasm	1
membrane	1
cell periphery	1
endosome	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
vesicle membrane	1
cellular_component	1
synaptic membrane	1
presynapse	1
lytic vacuole	1
endomembrane system	1
cell junction	1

Protein interactions and networks

STRING

474 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNRF2	UBE2D2	P51669	786
ZNRF2	A0A087WY85	A0A087WY85	693
ZNRF2	UBE2S	Q16763	597
ZNRF2	ZNRF4	Q8WWF5	595
ZNRF2	RNF2	Q99496	547
ZNRF2	CWC25	Q9NXE8	543
ZNRF2	RSPRY1	Q96DX4	533
ZNRF2	EAF1	Q96JC9	520
ZNRF2	CLXN	Q9HAE3	498
ZNRF2	GPATCH3	Q96I76	488
ZNRF2	METTL6	Q8TCB7	451
ZNRF2	ZNRF3	Q9ULT6	448
ZNRF2	PLEKHA8	Q96JA3	446
ZNRF2	RBM5	P52756	437
ZNRF2	SNX20	Q7Z614	434

IntAct

20 interactions, top by confidence:

A	B	Type	Score
UBE2N	UBA1	psi-mi:“MI:0914”(association)	0.640
YWHAG	SHTN1	psi-mi:“MI:0914”(association)	0.560
WDR5B	TCP1	psi-mi:“MI:0914”(association)	0.530
CHCHD4	ENSA	psi-mi:“MI:0914”(association)	0.530
SLC37A4	ZNRF2	psi-mi:“MI:0915”(physical association)	0.400
CGB1	ZNRF2	psi-mi:“MI:0915”(physical association)	0.400
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
YWHAH	SHTN1	psi-mi:“MI:0914”(association)	0.350
ABCA2	ABCD4	psi-mi:“MI:0914”(association)	0.350
NCKAP5	KIF3C	psi-mi:“MI:0914”(association)	0.350
ZNRF2	ANKRD28	psi-mi:“MI:0914”(association)	0.350
EEA1	HSBP1	psi-mi:“MI:0914”(association)	0.350
MYH3	MYH6	psi-mi:“MI:0914”(association)	0.350
WDR5B	HSPA8	psi-mi:“MI:0914”(association)	0.350
ZNRF2	BMH1	psi-mi:“MI:0914”(association)	0.350
UBE2N	ZNRF2	psi-mi:“MI:0915”(physical association)	0.000
ZNRF2	cca	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (80): ZNRF2 (Affinity Capture-MS), ATP1A1 (Biochemical Activity), UBC (Biochemical Activity), UBE2N (Reconstituted Complex), ZNRF2 (Affinity Capture-MS), MTOR (Affinity Capture-Western), RPTOR (Affinity Capture-Western), MLST8 (Affinity Capture-Western), ZNRF2 (Biochemical Activity), PPP6C (Affinity Capture-Western), ANKRD28 (Affinity Capture-Western), PPP6R3 (Affinity Capture-Western), ZNRF2 (Biochemical Activity), ATP6V0A2 (Affinity Capture-Western), LAMTOR1 (Affinity Capture-Western)

ESM2 similar proteins: A1L020, A1L3F4, A7X8B3, A7X8B5, A7X8B7, A7X8B9, A7X8C2, A7X8C4, A7X8C7, A7X8C9, A7X8D2, A7X8D4, A7XW25, O97775, O97776, O97952, O97960, P06401, P10275, P84550, P84551, P89463, Q01JD1, Q05A36, Q0VDT2, Q3UE17, Q5PQQ7, Q5U5Q3, Q69Z36, Q6QT55, Q6ZK57, Q6ZN04, Q71FD5, Q7RTV3, Q7TSJ6, Q7XQN1, Q7XT42, Q84SL2, Q86XN8, Q8BQ89

Diamond homologs: A0A0D1E015, A0JMD2, A1CEK1, A1DFP5, A2QWA2, A4QTV1, A8QCE4, A8XJZ8, B0G126, B0WAQ0, B3MT31, B3P851, B4G2G5, B4IC49, B4JHI7, B4K982, B4M140, B4NFJ7, B4PRU6, D2H5P6, D3ZVP7, D4A8G9, E1BLZ4, F1MM41, F7EP40, O13821, O14964, O59722, O76902, O95405, O96838, P0CS26, P0CS27, P34756, P40343, Q05B78, Q08CN9, Q0CJV3, Q0P4S0, Q0U4Z8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	ZNRF2	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

12 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	6
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1401 predictions. Top by Δscore:

Variant	Effect	Δscore
7:30323736:TGG:T	donor_loss	1.0000
7:30323737:GGT:G	donor_loss	1.0000
7:30323738:GTAA:G	donor_loss	1.0000
7:30323739:T:G	donor_loss	1.0000
7:30355832:GG:G	donor_gain	1.0000
7:30355833:GG:G	donor_gain	1.0000
7:30366052:A:G	acceptor_gain	1.0000
7:30323636:TTTTA:T	acceptor_loss	0.9900
7:30323637:TTTA:T	acceptor_loss	0.9900
7:30323638:TTAG:T	acceptor_loss	0.9900
7:30323639:TA:T	acceptor_loss	0.9900
7:30323640:A:AG	acceptor_gain	0.9900
7:30323640:A:C	acceptor_loss	0.9900
7:30323640:AG:A	acceptor_gain	0.9900
7:30323641:G:A	acceptor_loss	0.9900
7:30323641:G:GG	acceptor_gain	0.9900
7:30323641:GG:G	acceptor_gain	0.9900
7:30323738:G:GG	donor_gain	0.9900
7:30323740:AA:A	donor_loss	0.9900
7:30342792:A:G	donor_gain	0.9900
7:30355216:T:G	donor_gain	0.9900
7:30355244:T:G	donor_gain	0.9900
7:30355726:A:AG	acceptor_gain	0.9900
7:30355726:AGAG:A	acceptor_gain	0.9900
7:30355727:G:GG	acceptor_gain	0.9900
7:30355727:GA:G	acceptor_gain	0.9900
7:30355727:GAGG:G	acceptor_gain	0.9900
7:30366051:AAGAT:A	acceptor_gain	0.9900
7:30284475:G:GG	donor_gain	0.9800
7:30355834:G:GG	donor_gain	0.9800

AlphaMissense

1555 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:30323650:T:A	C160S	1.000
7:30323650:T:C	C160R	1.000
7:30323651:G:A	C160Y	1.000
7:30323651:G:C	C160S	1.000
7:30323652:C:G	C160W	1.000
7:30323659:T:A	C163S	1.000
7:30323659:T:C	C163R	1.000
7:30323660:G:A	C163Y	1.000
7:30323660:G:C	C163S	1.000
7:30323661:C:G	C163W	1.000
7:30323695:C:G	H175D	1.000
7:30323707:T:A	C179S	1.000
7:30323707:T:C	C179R	1.000
7:30323708:G:A	C179Y	1.000
7:30323708:G:C	C179S	1.000
7:30323708:G:T	C179F	1.000
7:30323709:T:G	C179W	1.000
7:30323731:T:C	Y187H	1.000
7:30323731:T:G	Y187D	1.000
7:30355757:T:A	C199S	1.000
7:30355757:T:C	C199R	1.000
7:30355758:G:A	C199Y	1.000
7:30355758:G:C	C199S	1.000
7:30355758:G:T	C199F	1.000
7:30355759:T:G	C199W	1.000
7:30355764:T:A	I201K	1.000
7:30355764:T:C	I201T	1.000
7:30355764:T:G	I201R	1.000
7:30355766:T:A	C202S	1.000
7:30355766:T:C	C202R	1.000

dbSNP variants (sampled 300 via entrez): RS1000044239 (7:30304966 T>C), RS1000069194 (7:30338993 G>A), RS1000113953 (7:30283481 G>A), RS1000143331 (7:30352421 C>A,T), RS1000198576 (7:30364549 T>G), RS1000238009 (7:30358840 G>T), RS1000251574 (7:30339535 G>T), RS1000254714 (7:30321166 C>G,T), RS1000274692 (7:30283072 A>G), RS1000305971 (7:30289641 A>C), RS1000334819 (7:30309232 T>G), RS1000344918 (7:30345289 A>G), RS1000363929 (7:30333365 T>A), RS1000396511 (7:30333689 T>C,G), RS1000450291 (7:30352194 G>A,C,T)

Disease associations

OMIM: gene MIM:612061 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002936_26	Cadmium levels	1.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases methylation, increases expression	2
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases methylation	1
urushiol	increases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
butyraldehyde	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
Bortezomib	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Caffeine	decreases phosphorylation	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Ozone	affects expression, increases abundance	1
Tretinoin	increases expression	1
Vincristine	decreases expression	1
Aflatoxin B1	decreases methylation	1
Asbestos, Serpentine	increases methylation	1
Antirheumatic Agents	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D8DK	Ubigene A-549 ZNRF2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.